GlaxoSmithKline PLC
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, infl… Read more
Market Cap & Net Worth: GlaxoSmithKline PLC (GSK)
GlaxoSmithKline PLC (LSE:GSK) has a market capitalization of $955.93 Million (GBX7.86 Trillion) as of March 21, 2026. Listed on the LSE stock exchange, this UK-based company holds position #29086 globally and #455 in its home market, demonstrating a -5.32% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GlaxoSmithKline PLC's stock price GBX1956.00 by its total outstanding shares 4016708266 (4.02 Billion).
GlaxoSmithKline PLC Market Cap History: 2015 to 2026
GlaxoSmithKline PLC's market capitalization history from 2015 to 2026. Data shows growth from $439.77 Million to $955.93 Million (8.09% CAGR).
Index Memberships
GlaxoSmithKline PLC is a constituent of 6 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE All-Share
FTAS
|
$61.40 Million | 14.23% | #2 of 573 |
|
FTSE 350
FTLC
|
$54.97 Million | 15.90% | #2 of 350 |
|
FTSE 100 Index (UK)
FTSE
|
$29.54 Million | 29.58% | #2 of 100 |
|
STOXX Europe Large 200 EUR Price
LCXP
|
$1.05 Trillion | 0.00% | #26 of 182 |
|
STOXX Europe Large 200 Net Return
LCXR
|
$1.05 Trillion | 0.00% | #26 of 182 |
|
FTSE 350 Pharmaceuticals & Biotechnology
NMX4570
|
$8.93 Million | 97.89% | #1 of 6 |
Weight: GlaxoSmithKline PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
GlaxoSmithKline PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GlaxoSmithKline PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.02x
GlaxoSmithKline PLC's market cap is 0.02 times its annual revenue
0.45x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.26x
GlaxoSmithKline PLC's market cap is 0.26 times its annual earnings
6.58x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $439.77 Million | $23.92 Billion | $8.42 Billion | 0.02x | 0.05x |
| 2016 | $525.83 Million | $27.89 Billion | $912.00 Million | 0.02x | 0.58x |
| 2017 | $468.95 Million | $30.19 Billion | $1.53 Billion | 0.02x | 0.31x |
| 2018 | $558.15 Million | $30.82 Billion | $3.62 Billion | 0.02x | 0.15x |
| 2019 | $699.45 Million | $33.75 Billion | $4.64 Billion | 0.02x | 0.15x |
| 2020 | $554.22 Million | $34.10 Billion | $5.75 Billion | 0.02x | 0.10x |
| 2021 | $702.00 Million | $24.70 Billion | $4.38 Billion | 0.03x | 0.16x |
| 2022 | $649.90 Million | $29.32 Billion | $14.96 Billion | 0.02x | 0.04x |
| 2023 | $681.97 Million | $30.33 Billion | $4.93 Billion | 0.02x | 0.14x |
| 2024 | $658.06 Million | $31.38 Billion | $2.58 Billion | 0.02x | 0.26x |
Competitor Companies of GSK by Market Capitalization
Companies near GlaxoSmithKline PLC in the global market cap rankings as of March 21, 2026.
Key companies related to GlaxoSmithKline PLC by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #14 globally with a market cap of $819.40 Billion USD.
- Johnson & Johnson (NYSE:JNJ): Ranked #17 globally with a market cap of $571.57 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #34 globally with a market cap of $364.02 Billion USD.
- AstraZeneca PLC (NASDAQ:AZN): Ranked #45 globally with a market cap of $291.59 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #14 | Eli Lilly and Company | NYSE:LLY | $819.40 Billion | $917.50 |
| #17 | Johnson & Johnson | NYSE:JNJ | $571.57 Billion | $237.60 |
| #34 | AbbVie Inc | NYSE:ABBV | $364.02 Billion | $206.23 |
| #45 | AstraZeneca PLC | NASDAQ:AZN | $291.59 Billion | $188.93 |
GlaxoSmithKline PLC Historical Marketcap From 2015 to 2026
Between 2015 and today, GlaxoSmithKline PLC's market cap moved from $439.77 Million to $ 955.93 Million, with a yearly change of 8.09%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX955.93 Million | +7.21% |
| 2025 | GBX891.66 Million | +35.50% |
| 2024 | GBX658.06 Million | -3.51% |
| 2023 | GBX681.97 Million | +4.94% |
| 2022 | GBX649.90 Million | -7.42% |
| 2021 | GBX702.00 Million | +26.66% |
| 2020 | GBX554.22 Million | -20.76% |
| 2019 | GBX699.45 Million | +25.32% |
| 2018 | GBX558.15 Million | +19.02% |
| 2017 | GBX468.95 Million | -10.82% |
| 2016 | GBX525.83 Million | +19.57% |
| 2015 | GBX439.77 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 20th, 2026 the market cap of GlaxoSmithKline PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $955.93 Million USD |
| MoneyControl | $955.93 Million USD |
| MarketWatch | $955.93 Million USD |
| marketcap.company | $955.93 Million USD |
| Reuters | $955.93 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.